PRF Technologies (PRFX) Amortization of Deferred Charges (2020)
PRF Technologies (PRFX) posted quarterly Amortization of Deferred Charges of $366000.0 for Q3 2020, up 41.31% on a QoQ basis from $259000.0 in Q2 2020.
PRF Technologies (PRFX) Amortization of Deferred Charges (2020) Analysis & Trends
PRF Technologies (PRFX) has reported Amortization of Deferred Charges for 1 consecutive years, with $366000.0 the latest figure, recorded in Q3 2020.
- Quarterly Amortization of Deferred Charges changed N/A year-over-year to $366000.0 in Q3 2020, while the trailing twelve-month figure through Dec 2020 was $987000.0 (changed N/A YoY) and the FY2020 annual result came in at $987000.0, up 82.44% from the prior year.
- Amortization of Deferred Charges climbed to $366000.0 in Q3 2020 per PRFX's latest filing, from $259000.0 in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for PRFX reached as high as $366000.0 in Q3 2020 and fell as low as $259000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.86 Bn | 88.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.84 Bn | 32.10 Bn | 1.97 Bn |
| 3 | Zoetis | 32.70 Bn | 30.76 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.73 Bn | 23.67 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - |
| 7 | Viatris | 20.18 Bn | 18.37 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.82 Bn | 16.50 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn |
| 10 | PRF Technologies | 728,969.63 | -3.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 366,000.00 |
| Sep 30, 2020 | 366,000.00 |
| Jun 30, 2020 | 259,000.00 |
| Jun 30, 2020 | 259,000.00 |
| Mar 31, 2020 | 362,000.00 |
| Mar 31, 2020 | 362,000.00 |